Individualized treatment for R0 surgery in advanced ovarian cancer

LIU Kai-jiang

doi:10.19538/j.fk2026010107

PDF(1006 KB)

Chinese Journal of Practical Gynecology and Obstetrics ›› 2026, Vol. 42 ›› Issue (1) : 28-31. DOI: 10.19538/j.fk2026010107

Individualized treatment for R0 surgery in advanced ovarian cancer

LIU Kai-jiang

Author information +

History +

Abstract

Achieving R0 resection during cytoreductive surgery for advanced ovarian cancer represents the most critical factor for improving patient prognosis. The success of R0 resection primarily depends on three factors： the extent of disease spread，the patient's overall condition，and the surgical team's expertise. R0 resection is an extremely complex systematic procedure and requires high degree of multidisciplinary collaboration. Emphasizing an individualized treatment approach—including selecting the optimal timing for surgery，the appropriate surgical technique，and the sufficient extent of resection—is essential to achieving satisfactory cytoreduction.

Key words

ovarian cancer / R0 surgery / individualized treatment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIU Kai-jiang. Individualized treatment for R0 surgery in advanced ovarian cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2026, 42(1): 28-31 https://doi.org/10.19538/j.fk2026010107

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1):17-48. DOI:10.3322/caac.21763. Cited in this article [1]

[2]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China,2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. DOI:10.1016/j.jncc.2024.01.006. Cited in this article [1]

[3]	Caruso G, Weroha SJ, Cliby W. Ovarian cancer: a review[J]. JAMA, 2025, 334(14):1278-1291. DOI:10.1001/jama.2025.9495. Cited in this article [1]

[4]	曹冬焱, 向阳. 卵巢癌手术质量控制[J]. 中国实用妇科与产科杂志, 2022, 38(1):29-32. DOI:10.19538/j.fk2022010108. Cited in this article [1]

[5]	Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis[J]. Semin Surg Oncol, 1994, 10(1):12-20. DOI:10.1002/ssu.2980100105. Cited in this article [1]

[6]	Reuss A, du Bois A, Harter P, et al. TRUST:Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)[J]. Int J Gynecol Cancer, 2019, 29(8):1327-1331. DOI:10.1136/ijgc-2019-000682. Cited in this article [2]

[7]	Melamed A, Rauh-Hain JA, Gockley AA, et al. Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer[J]. JAMA Oncol, 2021, 7(12):1782-1790. DOI:10.1001/jamaoncol.2021.4252. Cited in this article [1]

[8]	Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)[J]. Int J Gynecol Cancer, 2020, 30(11):1657-1664. DOI:10.1136/ijgc-2020-001640. Cited in this article [1]

[9]	Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage Ⅲ/Ⅳ ovarian,tubal and peritoneal cancers in phase Ⅲ randomised trial[J]. Eur J Cancer, 2020, 130:114-125. DOI:10.1016/j.ejca.2020.02.020. Cited in this article [1]

[10]	Jiang R, Feng Y, Chen Y, et al. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer:final overall survival analysis of the SOC-1 randomized phase 3 trial[J]. Nat Med, 2024, 30(8):2181-2188. DOI:10.1038/s41591-024-02981-0. Cited in this article [1]

[11]

Jochum

, Dumas

, Gougis

, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stageⅣovarian cancer:a nationwide population-based target trial emulation[J]. Am J Obstet Gynecol, 2025, 232(2):194.e1-194.e11. DOI:10.1016/j.ajog.2024.07.044.

Cited in this article [1]

[12]	朱连成, 林蓓. 新辅助化疗对卵巢癌肿瘤细胞减灭术手术结局的影响[J]. 中国实用妇科与产科杂志, 2023, 39(7):706-711. DOI:10.19538/j.fk2023070108. Cited in this article [1]

[13]

Hyun Kim

, Myong

Cheol Lim

, Sang-Yoon

Park

, et al. Survival outcomes of advanced ovarian cancer treated with neoadjuvant chemotherapy versus primary cytoreductive surgery using a quality-assured decision-making approach[J]. J Clin Oncol, 2025, 43:5577-557. DOI:10.1200/JCO.2025.43.16_suppl.5577.

Cited in this article [1]

[14]	Miceli V, Gennarini M, Tomao F, et al. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT,MRI,Radiomic Features and Resectability Criteria[J]. Cancers (Basel), 2023, 15(24):5827. DOI:10.3390/cancers15245827. Cited in this article [1]

[15]	Tsili AC, Alexiou G, Tzoumpa M, et al. Imaging of peritoneal metastases in ovarian cancer using MDCT,MRI,and FDG PET/CT: a systematic review and meta-analysis[J]. Cancers (Basel), 2024, 16(8):1467. DOI:10.3390/cancers16081467. Cited in this article [1]

[16]	Rauh-Hain JA, Melamed A, Pareja R, et al. Laparoscopic cytoreduction after neoadjuvant chemotherapy in high-grade epithelial ovarian cancer: a lance randomized clinical trial[J]. JAMA Netw Open, 2024, 7(11):e2446325. DOI:10.1001/jamanetworkopen.2024.46325. Cited in this article [1]

[17]	Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed,advanced ovarian cancer: ASCO guideline update[J]. J Clin Oncol, 2025, 43(7):868-891. DOI:10.1200/JCO-24-02589. Cited in this article [1]

[18]	Tsunoda AT, Dos Reis R, Moretti-Marques R, et al. Surgery in ovarian cancer-Brazilian Society of Surgical Oncology consensus[J]. J Surg Oncol, 2025, 132(4):640-653. DOI:10.1002/jso.70055. Cited in this article [1]

[19]	陈春林, 李维丽. 重视临床应用解剖学研究——对妇产科手术进行系统分区[J]. 中国实用妇科与产科杂志, 2025, 41(1):26-30. DOI:10.19538/j.fk2025010107. Cited in this article [1]

[20]	狄文, 张楠. 卵巢恶性肿瘤诊疗观念的思考与挑战[J]. 中国实用妇科与产科杂志, 2024, 40(11):1057-1060. DOI:10.19538/j.fk2024110101. Cited in this article [1]